FluidAI wins US FDA clearance for its surgical monitor as Waterloo's Youssef Helwa targets 100,000 operations
The healthtech startup spent five years and trials across four continents getting Origin to market. Now it has the clearance to sell into the world's largest healthcare system, and a plan to widen well beyond a single device.
FluidAI has secured US Food and Drug Administration 510(k) clearance for Origin, its bedside monitor for patients recovering from surgery, opening the door to the American market. The clearance, registered as K243965, lands the Kitchener-Waterloo company a Class 2 medical device approval it had been building toward for half a decade.
Origin attaches to standard surgical drains and analyses the biochemical makeup of patient fluid in real time, tracking pH, electrical conductivity and temperature. It sits at the sharp end of a wider AI infrastructure boom now reaching safety and healthcare equipment makers. The goal is to flag anastomotic leaks, one of the most dangerous complications after gastrointestinal surgery, within 48 hours and before symptoms typically appear. Left undetected, such leaks can escalate quickly into sepsis, repeat surgery or death, with incidence rates reaching as high as 30 per cent in some patient groups.
Co-founder and chief executive Youssef Helwa called the clearance a major milestone and "a foundational step toward a future of data-driven, post-operative recovery". He has argued that surgeons have long lacked a reliable answer to post-operative uncertainty, and that bedside data can drive earlier intervention. Reliability is the whole game in clinical settings, where the hallucination problems that have embarrassed AI reports elsewhere would be intolerable. One lesson from clinicians reshaped the product. Helwa has said surgeons wanted to know which patients would not develop complications, so they could be discharged sooner and hospital backlogs cleared. Business development manager Guen O'Hara described the approval as a milestone for the whole company that strengthens ties with US health systems.
The clinical traction is already there. FluidAI works with more than 35 medical centres, including the Cleveland Clinic in Ohio and Toronto's University Health Network, and is aiming to support patients across 100,000 total operations. The 85-person company has raised just over $20m to date, including a $15m Series A in 2023, and picked up $2m from FedDev Ontario to accelerate manufacturing.
The strategy now widens beyond hardware. Origin feeds Stream Care, an AI platform that scores complication risk, within a broader suite the company calls its Recovery Intelligence and Surgical Excellence programme. In May, FluidAI announced a collaboration with France's Qaelon Medical to link data from the operating room through to recovery, targeting anastomotic leaks across the full surgical journey. The bet is that continuous surgical intelligence, rather than one-off readings, is where the real clinical and commercial value sits. It is a thesis echoed across industries, with IBM's consulting chief warning that AI will "implode" unprepared rivals, even as the funding climate stays choppy and investors trim stakes in marquee names like Revolut.